Bloomage BioTechnology (SHSE:688363) Total Liabilities : ¥1,580 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Bloomage BioTechnology Total Liabilities?

Bloomage BioTechnology's Total Liabilities for the quarter that ended in Mar. 2025 was ¥1,580 Mil.

Bloomage BioTechnology's quarterly Total Liabilities increased from Sep. 2024 (¥1,634.75 Mil) to Dec. 2024 (¥1,816.93 Mil) but then declined from Dec. 2024 (¥1,816.93 Mil) to Mar. 2025 (¥1,579.57 Mil).

Bloomage BioTechnology's annual Total Liabilities declined from Dec. 2022 (¥1,998.77 Mil) to Dec. 2023 (¥1,486.58 Mil) but then increased from Dec. 2023 (¥1,486.58 Mil) to Dec. 2024 (¥1,816.93 Mil).

Bloomage BioTechnology Total Liabilities Historical Data

The historical data trend for Bloomage BioTechnology's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bloomage BioTechnology Total Liabilities Chart

Bloomage BioTechnology Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

Get a 7-Day Free Trial

764.03

1,801.28

1,998.77

1,486.58

1,816.93

Bloomage BioTechnology Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Liabilities	Get a 7-Day Free Trial															1,188.06	1,594.29	1,634.75	1,816.93	1,579.57

Bloomage BioTechnology Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Bloomage BioTechnology's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1341.03	+	(218.09	+	257.809
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,817

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	8656.732	-	6839.803
	=	1,817

Bloomage BioTechnology's Total Liabilities for the quarter that ended in Mar. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1120.83	+	(202.702	+	256.041
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	1,580

Total Liabilities	=	Total Assets (Q: Mar. 2025 )	-	Total Equity (Q: Mar. 2025 )
	=	8537.343	-	6957.77
	=	1,580

Bloomage BioTechnology Total Liabilities Related Terms

Thank you for viewing the detailed overview of Bloomage BioTechnology's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Bloomage BioTechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » Bloomage BioTechnology Corp Ltd (SHSE:688363) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 678 Tianchen Avenue, High-Tech Development Zone, Shandong Province, Jinan City, CHN

Website

http://www.bloomagebio-tech.com

Bloomage BioTechnology Corp Ltd manufactures and sells a variety of chemicals and chemical-based products, typically made from hyaluronic acid sodium, or HA. The firm organizes itself into two segments based on product type. The HA raw materials segment, which generates the majority of revenue, sells HA and HA derivatives produced using bio-fermentation technology. The HA raw materials segment products are classified into three grades of HA: medicine grade, cosmetic grade, and food grade. The HA end products segment sells medical skin care products, bone products for intra-articular injection, and medical beauty devices. The majority of revenue comes from China.

Executives

Zhao Yi	Core technical personnel
Luan Yi Hong	Core technical personnel
Shi Yan Li	Core technical personnel
Liu Jian Jian	Core technical personnel
Wang Yu Ling	Core technical personnel
Zhou Wei	Core technical personnel
Huang Si Ling	Core technical personnel
Han Hong Ling	Core technical personnel
Lu Zhen	Core technical personnel

Bloomage BioTechnology Headlines

No Headlines